Eisai Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Haruo Naito
- Full Time Employees
- 10,543
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 4-6-10, Koishikawa Tokyo TY Japan 112-8088
- IPO Date
- Sep 14, 1961
- Website
- eisai.co.jp
- Similar Companies
- Business
- Eisai Co., Ltd. (4523.T) develops, manufactures and markets prescription pharmaceuticals with a focus on neurology and oncology. Founded in 1941 and headquartered in Tokyo, Japan, the company operates globally through subsidiaries and affiliates in the United States, Europe, Asia, Latin America, the Middle East and other regions, with manufacturing sites in Japan, the United States, China, India and the United Kingdom. Eisai offers a portfolio of branded products including LEQEMBI (lecanemab), a humanized monoclonal antibody targeting amyloid-beta protofibrils for early Alzheimer's disease approved in over 48 countries; LENVIMA (lenvatinib), an oral multi-receptor tyrosine kinase inhibitor approved in more than 80 countries for thyroid cancer, hepatocellular carcinoma and other indications often in combination with pembrolizumab or everolimus; DAYVIGO (lemborexant), an orexin receptor antagonist for insomnia approved in over 25 countries; Fycompa (perampanel), a selective AMPA receptor antagonist as adjunctive therapy for partial-onset and primary generalized tonic-clonic seizures approved in over 75 countries; and other therapies such as Aciphex/Pariet (rabeprazole) for gastroesophageal reflux disease, URECE (dotinurad) for gout, TASFYGO (tasurgratinib) for biliary tract cancer with FGFR2 alterations, Rozobalamin (mecobalamin) for amyotrophic lateral sclerosis, and diagnostic products. In recent developments, Eisai completed a tender offer in May 2025 to make EcoNaviSta Inc. a wholly-owned subsidiary following a July 2024 business alliance, integrating EcoNaviSta's "Life Rhythm Navi" SaaS monitoring services into its dementia platform to enhance early detection and home care solutions; entered a February 2025 license agreement with SciClone Pharmaceuticals for tasurgratinib commercialization in Greater China; launched LEQEMBI IQLIK subcutaneous maintenance dosing in the United States in October 2025 with further regulatory submissions and approvals including Japan and the United Kingdom; received FDA approval in August 2025 for LEQEMBI IQLIK subcutaneous injection and presented long-term data showing potential delay in Alzheimer's progression; and advanced oncology combinations such as LENVIMA with belzutifan meeting primary endpoints in renal cell carcinoma trials in October 2025.
Company News
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
BioArctic Interim Report for the period January - March 2026
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
BioArctic Interim Report for the period October - December 2025
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript